Empagliflozin (EMPA), an inhibitor of sodium/glucose cotransporter 2 (SGLT2) in clinical use to treat type II diabetes and as of late also nondiabetic heart failure (HF) (9, 10), was recently shown to modulate cardiac Na+ channels. This evidence concerns the gene SLC5A2 and hydrops fetalis.